340 related articles for article (PubMed ID: 19859039)
1. Pancreatic cancer stem cells and EMT in drug resistance and metastasis.
Sarkar FH; Li Y; Wang Z; Kong D
Minerva Chir; 2009 Oct; 64(5):489-500. PubMed ID: 19859039
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer stem cells: emerging target for designing novel therapy.
Li Y; Kong D; Ahmad A; Bao B; Sarkar FH
Cancer Lett; 2013 Sep; 338(1):94-100. PubMed ID: 22445908
[TBL] [Abstract][Full Text] [Related]
3. Targeting pancreatic cancer stem cells for cancer therapy.
Xia J; Chen C; Chen Z; Miele L; Sarkar FH; Wang Z
Biochim Biophys Acta; 2012 Dec; 1826(2):385-99. PubMed ID: 22728049
[TBL] [Abstract][Full Text] [Related]
4. Markers of pancreatic cancer stem cells and their clinical and therapeutic implications.
Gzil A; Zarębska I; Bursiewicz W; Antosik P; Grzanka D; Szylberg Ł
Mol Biol Rep; 2019 Dec; 46(6):6629-6645. PubMed ID: 31486978
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell in the progression and therapy of pancreatic cancer.
Xu L
Front Biosci (Landmark Ed); 2013 Jun; 18(3):795-802. PubMed ID: 23747847
[TBL] [Abstract][Full Text] [Related]
6. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.
Singh A; Settleman J
Oncogene; 2010 Aug; 29(34):4741-51. PubMed ID: 20531305
[TBL] [Abstract][Full Text] [Related]
7. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
Mitra A; Mishra L; Li S
Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
[TBL] [Abstract][Full Text] [Related]
8. CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-κB Pathway.
Zhang L; Wang D; Li Y; Liu Y; Xie X; Wu Y; Zhou Y; Ren J; Zhang J; Zhu H; Su Z
PLoS One; 2016; 11(8):e0158529. PubMed ID: 27505247
[TBL] [Abstract][Full Text] [Related]
9. Signalling mechanism(s) of epithelial-mesenchymal transition and cancer stem cells in tumour therapeutic resistance.
Cai Z; Cao Y; Luo Y; Hu H; Ling H
Clin Chim Acta; 2018 Aug; 483():156-163. PubMed ID: 29709449
[TBL] [Abstract][Full Text] [Related]
10. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.
Ahmed N; Abubaker K; Findlay J; Quinn M
Curr Cancer Drug Targets; 2010 May; 10(3):268-78. PubMed ID: 20370691
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cells and tumor metastasis.
Sun S; Qiu XS
J Cancer Res Ther; 2013 Nov; 9 Suppl():S150-2. PubMed ID: 24516051
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer: understanding and overcoming chemoresistance.
Wang Z; Li Y; Ahmad A; Banerjee S; Azmi AS; Kong D; Sarkar FH
Nat Rev Gastroenterol Hepatol; 2011 Jan; 8(1):27-33. PubMed ID: 21102532
[TBL] [Abstract][Full Text] [Related]
13. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
14. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.
Wang Z; Li Y; Ahmad A; Azmi AS; Kong D; Banerjee S; Sarkar FH
Drug Resist Updat; 2010; 13(4-5):109-18. PubMed ID: 20692200
[TBL] [Abstract][Full Text] [Related]
15. Metabolic Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the Epithelial-Mesenchymal Transition Program.
Aguilar E; Marin de Mas I; Zodda E; Marin S; Morrish F; Selivanov V; Meca-Cortés Ó; Delowar H; Pons M; Izquierdo I; Celià-Terrassa T; de Atauri P; Centelles JJ; Hockenbery D; Thomson TM; Cascante M
Stem Cells; 2016 May; 34(5):1163-76. PubMed ID: 27146024
[TBL] [Abstract][Full Text] [Related]
16. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
17. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic.
Voulgari A; Pintzas A
Biochim Biophys Acta; 2009 Dec; 1796(2):75-90. PubMed ID: 19306912
[TBL] [Abstract][Full Text] [Related]
19. Sanguinarine inhibits pancreatic cancer stem cell characteristics by inducing oxidative stress and suppressing sonic hedgehog-Gli-Nanog pathway.
Ma Y; Yu W; Shrivastava A; Alemi F; Lankachandra K; Srivastava RK; Shankar S
Carcinogenesis; 2017 Oct; 38(10):1047-1056. PubMed ID: 28968696
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.
Tanase CP; Neagu AI; Necula LG; Mambet C; Enciu AM; Calenic B; Cruceru ML; Albulescu R
World J Gastroenterol; 2014 Aug; 20(31):10790-801. PubMed ID: 25152582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
